Iron chelation: a potential therapeutic strategy in oesophageal cancer. (25th February 2013)

• Record Type: Journal Article
• Authors: Keeler, BD; Brookes, MJ
• Is Part Of: British journal of pharmacology. Volume 168:Number 6(2013:Mar.)
• Page Start: 1313
• Page End: 1315
• Publication Date: 2013-02-25
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.12093
• Languages: English
• ISSNs: 0007-1188

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12093-sec-1001" sec-type="section"> <p>Raised intracellular iron has been identified as a potential aetiological factor in the development of several epithelial malignancies, including those of the gastrointestinal tract. The mechanism behind this increase is thought to include disorders of iron uptake and storage. Several iron chelators have been identified as potential anti‐tumour agents, with much work undertaken to ascertain the exact mode of action. Despite this, there is little known about the role that these drugs play in the cellular iron metabolism of oesophageal cancer. Consequently, the present study looks to review the relationship of two clinically important iron‐chelating agents, deferoxamine and deferasirox, on cellular iron uptake and storage in oesophageal squamous and adenocarcinoma. This provides important evidence for the debate about the role these agents have in the clinical management of such tumours.</p> </sec> <sec id="bph12093-sec-0001" sec-type="relatedArticles"> <title>Linked Article</title> <p>This article is a commentary on Ford <italic>et al</italic>., pp. 1316–1328 of this issue. To view this paper visit http://dx.doi.org/10.1111/bph.12045</p> </sec> </abstract>